강직성 척추염 시장 규모, 점유율, 성장 분석 : 약제 클래스별, 유통 채널별, 지역별 - 산업 예측(2026-2033년)

Global Ankylosing Spondylitis Market size was valued at USD 7.28 Billion in 2024 and is poised to grow from USD 7.82 Billion in 2025 to USD 13.84 Billion by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).

The global ankylosing spondylitis market is witnessing remarkable growth fueled by factors influencing diagnosis, treatment, and management of this chronic inflammatory disease affecting the spine and joints. Key drivers include a rising prevalence of the condition and heightened awareness, leading to earlier detection due to improved diagnostic methods. Moreover, advancements in medical research and novel therapies have broadened treatment options, appealing particularly to the aging population that is more susceptible to the disease. Effective medications, such as NSAIDs and biologics like TNF inhibitors, enhance patient quality of life, increasing market demand. Nonetheless, challenges remain, including underdiagnosis due to vague symptoms, high treatment costs, limited healthcare access, and the necessity for continuous disease management without a definitive cure.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Market Segments Analysis

Global Ankylosing Spondylitis Market is segmented by Drug Class, Distribution Channel and region. Based on Drug Class, the market is segmented into Non-Steroidal Anti Inflammatory Drug (NSAID), TNF Inhibitors and Other Drug Classes. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Market

The Global Ankylosing Spondylitis market is experiencing growth driven by significant advancements in medical research that have enhanced the understanding of the disease and its mechanisms. The introduction of innovative targeted therapies, including tumor necrosis factor (TNF) inhibitors and interleukin inhibitors, has transformed the management of ankylosing spondylitis, offering patients more effective treatment options. Furthermore, the continuous development of treatment guidelines and the increasing availability of these potent medications are facilitating improved patient outcomes. Together, these factors are fostering a more comprehensive approach to managing this chronic condition, thereby supporting the expansion of the market dedicated to ankylosing spondylitis care.

Restraints in the Global Ankylosing Spondylitis Market

The global ankylosing spondylitis market faces certain constraints due to the necessity for long-term management and ongoing treatment of the condition. Effective disease control heavily relies on patients' compliance with prescribed medication regimens, commitment to lifestyle modifications, and participation in regular follow-ups. These factors present various challenges, such as maintaining patient adherence and adjusting daily habits, which can ultimately affect the overall growth of the market. Furthermore, the complexities involved in monitoring the disease pose additional obstacles, highlighting the need for constant engagement and support for individuals living with ankylosing spondylitis.

Market Trends of the Global Ankylosing Spondylitis Market

The Global Ankylosing Spondylitis market is witnessing a significant trend towards prioritizing early diagnosis and treatment, driven by the recognition of its impact on patient outcomes. Increased awareness among healthcare providers and patient advocacy organizations is fostering educational initiatives that underscore the importance of timely detection and intervention. This proactive approach enables healthcare professionals to initiate appropriate therapies promptly, effectively managing inflammation and mitigating disease progression. The trend is likely to spur the demand for advanced diagnostic tools and innovative therapeutic solutions, ultimately contributing to enhanced quality of life for patients and expanding opportunities within the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Ankylosing Spondylitis Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Non-Steroidal Anti Inflammatory Drug(NSAID)
• TNF Inhibitors
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia
  • Other TNF Inhibitors
• Other Drug Classes

Global Ankylosing Spondylitis Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Ankylosing Spondylitis Market Size & CAGR (2026-2033)

• North America (Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Izana Bioscience (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations